L3VLUP
ProSign in

VKTX in the 13F filings

Viking Therapeutics Inc · CUSIP 92686J106

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
latest of these filings; the earliest 14 Nov 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 1 listed it in both
Shares listed
4,837,655
combined, among listed positions
Reported value
$54m
combined, at the quarter end

Managers listing VKTX in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Viking Global Investors LP4,573,316$51m0.21%Added+1,028,81014 Nov 2023 (the filing on sec.gov)
Hudson Bay Capital Management LP214,339$2.4munder 0.1%Newnew14 Nov 2023 (the filing on sec.gov)
Moore Capital Management LP50,000$554kunder 0.1%Newnew14 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (2)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 4 in Q2 2026

Tracked managers listing it, at least.

024682019202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
VKTX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20181$949kn.a.n.a.
Q3 20183$20mn.a.n.a.
Q4 20181$161kn.a.n.a.
Q1 20191$6.5mn.a.n.a.
Q2 20192$5.4mn.a.n.a.
Q3 20191$751kn.a.n.a.
Q4 20201$112kn.a.n.a.
Q1 20211$245kn.a.n.a.
Q2 20212$1.0mn.a.n.a.
Q3 20212$769kn.a.n.a.
Q4 20211$627kn.a.n.a.
Q1 20221$290kn.a.n.a.
Q2 20221$849kn.a.n.a.
Q3 20222$3.5mn.a.n.a.
Q4 20223$13mn.a.n.a.
Q1 20234$71mn.a.n.a.
Q2 20231$57mn.a.n.a.
Q3 20233$54mn.a.n.a.
Q4 20232$138m21
Q1 20247$1.6bn52
Q2 20245$961m51
Q3 20245$1.1bn23
Q4 20246$794m43
Q1 20254$61m42
Q2 20253$72m30
Q3 20256$117m60
Q4 20256$202m189
Q1 20262$156m1018
Q2 20264$183m206

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

VKTX and LLY →VKTX and JNJ →VKTX and VRTX →Choose a stock to compare with VKTX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own VKTX, latest filings →Back to the 13F Explorer →